Ranbaxy Labs is to announce its Q3CY2008 numbers. According to CNBC-TV18 estimates, its Q3 consolidated net profit is seen going down by 76% at Rs 50 crore versus Rs 207.40 crore.

Its net sales are expected to go up by 23% at Rs 2,015.07 crore versus Rs 1,641.40 crore. Its operating profit is likely to go up at Rs 348.5 crore from Rs 283.10 crore. Operating profit margin is seen going up at 17.29% versus 17.25%.

Factors to watch for:

PAT de-growth on account of MTM loss on FCCB

Company is unlikely to take benefit of depreciation of the rupee due to forward covers (worth over $10 billion)

Sales growth on account of growth in Emerging markets and US.

(In previour quarter, there was an extraordinary gain of Rs 32.5 crore on sale of land & building)